Latest News





09-30-15 Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial
09-23-15 Zogenix to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
09-03-15 Zogenix to Participate in the Wells Fargo 2015 Healthcare Conference

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. The Relday Multi-Dose study was initiated in January and results are anticipated in Q3 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.